# About This Desk | Peptide Research Alliance

> What Peptide Research Alliance is, how it selects and cites literature, and what it is not — no clinic, no vendor, no prescriptions.

An independent literature digest. Not a clinic, not a vendor, not a recommendation engine.

## What this desk is

Peptide Research Alliance is an independent editorial resource covering the five research peptides people ask about most: Retatrutide, BPC-157, Ipamorelin, PT-141, and NAD+. The goal is a single, reliable desk where someone who has encountered one of these compounds in a health or research context can quickly understand what it is, how it works, and what the published evidence actually says — without wading through promotional copy, vendor landing pages, or community posts that mix real findings with wishful thinking.

This site is run as an editorial digest. All content is produced by human writers with expertise in science communication. All substantive claims are tied to cited, publicly accessible sources — PubMed, ClinicalTrials.gov, peer-reviewed journals, FDA prescribing information. Where the evidence is thin, we say so. Where it is strong, we say that too.

## Editorial method

**Source selection:** We prioritize peer-reviewed clinical trials, regulatory documents (FDA prescribing information, WADA prohibited list), systematic reviews, and pharmacokinetic studies over observational reports, case studies, or conference abstracts. For community-reported effects (which we cover in a clearly labeled "anecdotal" section on each compound page), we draw from accessible, publicly documented community discussions and published qualitative analyses.

**Citation practice:** Every factual claim about a compound's mechanism, study finding, regulatory status, or safety caution is attributed to a specific source listed in our references. We do not paraphrase without attribution. We do not extrapolate findings from one species to another without noting the difference. We do not describe animal findings as human evidence.

**Accuracy guards:** Each compound has specific compliance constraints that govern our coverage — for example, we do not apply the informal label "GLP-3" to retatrutide (it is a misnomer in the scientific literature), we correctly identify PT-141's FDA-approved scope as HSDD in premenopausal women only, and we distinguish NAD+ from its precursors NMN and NR throughout.

**What we do not do:** We do not provide dosing advice. We do not recommend products or suppliers. We do not have financial relationships with any vendor of any of the compounds covered here. We do not have sponsored content. No content on this site should be construed as medical advice.

## Independence and disclaimer

Peptide Research Alliance has no commercial relationship with any manufacturer, supplier, or clinic dealing in any of the compounds covered on this site. No advertising is accepted that promotes the sale of research compounds or their precursors.

The content on this site is for informational and educational purposes only. It summarizes publicly available published research. It is not medical advice, does not constitute a clinical recommendation, and does not suggest any individual should use any compound described here. Regulatory status information reflects publicly available sources as of the date of publication and may change; readers should verify current regulatory status independently.

If you are a researcher or clinician seeking to access compounds for legitimate research or therapeutic use, consult the relevant regulatory bodies and follow applicable laws in your jurisdiction.

---

An independent literature desk where every enthusiastic claim is immediately grounded in a citation and every gap in the evidence is stated plainly.